




PHARMACEUTICAL 2021

Larimar Therapeutics Inc.
Rank 111 of 402





RealRate

PHARMACEUTICAL 2021

Larimar Therapeutics Inc.
Rank 111 of 402



The relative strengths and weaknesses of Larimar Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Larimar Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Larimar Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 187%, being 139% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	97,952
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,992
Liabilities, Non-Current	6,002
Other Assets	5,694
Other Compr. Net Income	2.0
Other Expenses	0
Other Liabilities	0
Other Net Income	322
Other Revenues	0
Property and Equipment	1,040
Research and Development	31,407
Selling, General and Administrative Expense	11,397

Output Variable	Value in 1000 USD
Assets	104,686
Liabilities	14,994
Expenses	42,804
Revenues	0
Stockholders Equity	89,692
Net Income	-42,482
Comprehensive Net Income	-42,481
Economic Capital Ratio	187%